Peptide from sea bacterium may turn the tide of MRSA resistance

Peptide from Solomon Isles bug may turn the tide of MRSA resistance

Marine bacteria may yield the next generation of MRSA fighting drugs according to a team that used a peptide from a Pacific Ocean bug to render the hospital superbug less lethal.

The research showed that Solonamide B - a peptide extracted from a bug called Photobacterium halotolerans that is found in the Solomon Islands - stops staphylococci making both the toxins that can kill infected patients and the proteins that help resistant strains like MRSA withstand treatment.

This finding – which builds on the earlier discovery that Solonamide B interferes with how superbugs communicate– has significant implications for scientists trying to develop much needed alternatives to antibiotics according to lead researcher, Prof Hanne Ingmer.

She told in-Pharmatechnologist.com that: “I believe that the compounds have the potential to both treat and prevent infections.

The important difference compared to antibiotics is that the compound here does not kill the bacteria but "just" reduce their ability to produce toxins and other toxic molecules and it is the subsequent action of the immune system that we’re relying on for eradication.”

New treatments

The drug industry has seemingly lost interest in developing new antibiotics over the past 30 years, which is a problem because bacteria like MRSA have become resistant to available products and – as a result – infections have become increasingly difficult to treat.

More recently some drug firms have started showing renewed interest in antibiotic development with Swiss giant Roche being the most notable example, but more ways of combatting resistant bacteria are still needed.

In September the US Centers for Disease Control and Prevention (CDC) published a report on “antibiotic resistance threats” in which director Tom Frieden lamented the lack of new drugs in industry pipelines.

Until now, we have seen a steady pipeline of new antibiotics coming on to the market. But unfortunately, it does seem that the pipeline is nearly empty for the short-term. And experts tell us new drugs could be nearly a decade away.”

With this in mind we asked Prof Ingmer – whose team has started assessing whether antivirulence compounds like Solonamide B could work in animals – whether any drugmakers have expressed an interest in developing resistance proof alternatives to antibiotics.

We have not yet been in contact with any pharmaceutical companies but we are very interested in such collaborations.”

Related News

Scouring the seas to find new pharma ingredients

Scientists ‘all at sea’ to discover new pharma compounds

French deal sees peptide maker acquired by Provence Technologies

French deal sees peptide maker acquired by Provence Technologies

Ease regulations to cure drug industry antibiotic resistance, says RPS

Ease regulations to cure drug industry antibiotic resistance, says RPS

Scientists hail bottom-up design as the ‘souped-up car’ of proteins

Scientists hail bottom-up design as the ‘souped-up car’ of proteins

EMA says polymyxins can be given via nebuliser to treat Pseudomonas aeruginosa in cystic fibrosis patients

Superbug-driven surge in polymyxin demand prompts EMA to reassess safety info

Merck & Co set to lead fight against MRSA through Cubist buy, depsite US Cubicin patent ruling

Merck & Co set to be superbug-busting superstar despite US Cubicin ruling, analyst

Japan's Sosei Group buys peptide synthesis technology firm Jitsubo for $70m

Sosei looks to $23bn peptide market with acquisition of tech firm Jitsubo

Cone snails could be a source of pharma ingredients

Insulin in sea snail venom could be used by drug developers

Davos hosts the World Economic Forum this week

Antibiotics "a terrible business model" for Pharmas expert tells Davos

A metal organic framework (MOF) based on sea urchin shells could help deliver drugs and protect vaccines

CSIRO tells of sea shells that protect sensitive cures

New technique can accelerate antibiotic discovery says US team

'Bacterial autopsies' can speed up antibiotic discovery say US scientists

Selcia Gets Cantab Contract to Develop Superbug Busting Antibiotics

Selcia Gets Cantab Contract to Develop Superbug Busting Antibiotics

Avoiding Cross-Contamination in Antibiotic Manfacturing, the FDA Way

Avoiding Cross-Contamination in Antibiotic Manfacturing, the FDA Way

US FDA: Tetracycline Shortage To Go On

Tetracycline Shortage To Go On as US FDA Cannot Find New Source

GSK partners to grow Brazilian green chem expertise

GSK partners with Brazilian chem experts to make drugmaking greener

UK's Patent Box encouraged recent investments, GSK says

British manufacturing boosted by further GSK investments

Related Products

See more related products